High Growth Tech Stocks In The US Market With Promising Potential

As the United States market shows signs of resilience with major indices like the Dow Jones and S&P 500 poised for weekly and monthly gains, tech giants such as Amazon and Apple have reported strong quarterly results, boosting market sentiment. In this environment, identifying high-growth tech stocks involves looking at companies that are not only innovating but also effectively navigating current economic conditions to capitalize on emerging opportunities.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Exelixis	10.58%	20.15%	★★★★★☆
Palantir Technologies	25.12%	31.65%	★★★★★★
Workday	11.20%	32.07%	★★★★★☆
RenovoRx	65.52%	68.63%	★★★★★☆
OS Therapies	56.64%	68.61%	★★★★★☆
Gorilla Technology Group	32.75%	122.61%	★★★★★☆
Circle Internet Group	27.53%	82.41%	★★★★★☆
Aldeyra Therapeutics	42.92%	73.80%	★★★★★☆
Vanda Pharmaceuticals	23.06%	68.52%	★★★★★☆
Zscaler	15.74%	40.94%	★★★★★☆

Click here to see the full list of 74 stocks from our US High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Agios Pharmaceuticals (AGIO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medicines in the field of cellular metabolism in the United States, with a market cap of $2.51 billion.

Operations: Agios Pharmaceuticals specializes in the discovery and development of cellular metabolism-based medicines. The company operates primarily within the biopharmaceutical sector, with its business model centered on innovative drug development.

Agios Pharmaceuticals, despite a challenging financial period marked by a net loss of $304.74 million for the nine months ending September 2025, is demonstrating significant potential in the biotech sector with its innovative drug, PYRUKYND®. This oral pyruvate kinase activator has recently received positive opinions from European regulators for new therapeutic indications, reflecting its growing influence in treating complex diseases like thalassemia. The company's commitment to research and development is underscored by an impressive annual revenue growth forecast of 57.2% and earnings growth projection at 43.6%, signaling robust future prospects amidst current volatility.

• Click to explore a detailed breakdown of our findings in Agios Pharmaceuticals' health report.

• Examine Agios Pharmaceuticals' past performance report to understand how it has performed in the past.

Krystal Biotech (KRYS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $5.36 billion.

Operations: Krystal Biotech generates revenue primarily from its genetic medicines segment, which amounted to $359.21 million. The company is engaged in the discovery, development, manufacturing, and commercialization of these medicines targeting diseases with significant unmet medical needs in the U.S.

Krystal Biotech's recent FDA platform technology designation for its KB801 gene therapy underscores the company's innovative edge in biotechnology, particularly in treating rare diseases like neurotrophic keratitis. This designation could streamline development and review processes significantly, enhancing Krystal's operational efficiency. The company's robust pipeline across diverse medical fields complements a strong financial trajectory, with an annual revenue growth rate of 26.1% and earnings expected to surge by 32.7% annually. Such figures not only reflect Krystal Biotech’s solid market positioning but also its potential to sustain high growth amidst dynamic industry challenges.

• Unlock comprehensive insights into our analysis of Krystal Biotech stock in this health report.

• Learn about Krystal Biotech's historical performance.

monday.com (MNDY)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: monday.com Ltd., along with its subsidiaries, develops software applications globally, including in the United States, Europe, the Middle East, Africa, and the United Kingdom, with a market cap of approximately $10.10 billion.

Operations: monday.com generates revenue primarily from its Internet Software & Services segment, amounting to $1.10 billion. The company operates globally, focusing on developing software applications across various regions.

Amidst a dynamic tech landscape, monday.com stands out with its aggressive push into AI-driven solutions. At its recent Elevate conference, the company unveiled significant product innovations like monday agents and monday vibe, which simplify complex tasks through no-code AI tools. These enhancements are pivotal as they transition from supporting to executing end-to-end business functions, potentially reshaping operational efficiencies across industries. Financially, the firm is on a robust trajectory with a projected annual revenue growth of 17.5% and earnings expected to surge by 36.6%. Additionally, the recent authorization of an $870 million share repurchase program underscores confidence in its financial health and commitment to shareholder value.

• Delve into the full analysis health report here for a deeper understanding of monday.com.

• Review our historical performance report to gain insights into monday.com's's past performance.

Turning Ideas Into Actions

• Access the full spectrum of 74 US High Growth Tech and AI Stocks by clicking on this link.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com